| Identification | Back Directory | [Name]
Levemir (tn) | [CAS]
169148-63-4 | [Synonyms]
D04539
Levemir
Levemir (tn)
Insulin detemir
Levemir (tn) USP/EP/BP
Insulin detemir (usan/inn)
Insulin detemir (genetical recombination)
Recombinant Insulin Detemir protein (HEK293)
Insulin detemir (genetical recombination) (jan) | [Molecular Formula]
C267H402N64O76S6 | [MOL File]
169148-63-4.mol | [Molecular Weight]
5916.82 |
| Hazard Information | Back Directory | [Uses]
Antidiabetic. | [in vivo]
Insulin Detemir (d-INS) (5 IU/kg; i.p.; once daily; 2 weeks) demonstrates weight-sparing effects compared with other insulin formulations, and shows a intestinal tissues preference, potentially involving the activation of insulin/-catenin/CREB signaling pathways[1].
| Animal Model: | Obese type 2 diabetic db/db mice[1] | | Dosage: | 5 IU/kg | | Administration: | Intraperitoneal injection; once daily for 2 weeks | | Result: | Decreased body weight of the mice after 14-day daily injection of d-INS (5 IU/kg) significantly compared with those injected with the same dose of human Insulin or saline.
Induced rapid phosphorylation of protein kinase B (Akt) in the gut L cells of normal mice. |
|
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
www.biorbyt.com |
|